apl. Prof. Dr. Lucie Heinzerling

Medizinische Fakultät Department of Dermatology

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life (2022) Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, Kähler KC, et al. Journal article Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study (2022) Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, et al. Journal article Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma (2022) Cartun Z, Kunz WG, Heinzerling L, Tomsitz D, Guertler A, Westphalen CB, Ricke J, et al. Journal article Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence (2022) Vera J, Lai X, Baur A, Erdmann M, Gupta S, Gutta C, Heinzerling L, et al. Journal article, Review article Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Bluhm L, Grimmelmann I, Gutzmer R, Meier F, Garzarolli M, et al. Conference contribution Patient preferences of German and Swiss melanoma patients with regard to life-threatening side effects in the context of adjuvant immunotherapy - a qualitative GerMelaTox-A substudy (2022) Peters W, Maul LV, Huning S, Hassel JC, Heinzerling L, Loquai C, Gutzmer R, et al. Conference contribution Tolerability and efficacy of BRAF and MEK inhibitors for metastasized melanoma after intra-class switch: a multicenter, retrospective study (2022) Salzmann M, Wald A, Stege H, Loquai C, Zimmer L, Hayani K, Heinzerling L, et al. Conference contribution Pigmented lesions of the mucosa (2022) Heppt M, Heinzerling L Journal article BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation (2021) Hoyer S, Eberlein V, Schuler G, Berking C, Heinzerling L, Schaft N, Dörrie J Journal article, Original article